Pregnancy after breast cancer: latest evidence and practical considerations
- PMID: 40538639
- PMCID: PMC12177258
- DOI: 10.1177/17588359251346648
Pregnancy after breast cancer: latest evidence and practical considerations
Abstract
Advancements in breast cancer care have significantly improved survival rates in women of all ages; however, young survivors face unique challenges related to fertility, pregnancy, and maternal-fetal health which may impact on their medical and psychosocial outcomes. Increasingly, young women are diagnosed with breast cancer before completing their reproductive plans and goals and may undergo gonadotoxic therapies and prolonged endocrine therapy with age-related fertility decline. Pretreatment counseling is critical to manage expectations, align reproductive and treatment goals, plan future childbearing opportunities, and refer for fertility preservation interventions when needed. Evidence supports the safety of pregnancy and breastfeeding in posttreatment scenarios, with individual risks and treatment histories carefully evaluated. The growing use of novel agents like CDK4/6 inhibitors, poly-ADP-ribose polymerase inhibitors, and immune checkpoint inhibitors for which there are little to no data regarding impact on fertility highlights the urgent need for further research in this area. Patient-centered, multidisciplinary approaches applied throughout the disease trajectory remain essential to support the reproductive health and overall quality of life of young breast cancer survivors navigating the reproductive complexities of modern breast cancer treatment.
Keywords: breast cancer; fertility; gonadotoxicity; pregnancy; young women.
© The Author(s), 2025.
Conflict of interest statement
T.S. reports honorarium from Roche, Eli Lilly, Novartis, MSD, Gilead, Astrazeneca and Stemline, advisory from Novartis, Roche and travel support for Roche, Gilead, Oncotest, Pfizer, Stemline, and Astra-Zeneca. A.H.P. reports research support from Patient-Centered Outcomes Research Institute (AFT-25 COMET), Susan G. Komen, the Breast Cancer Research Foundation (BCRF) and the American Cancer Society (ACS); and royalties from Wolters Kluwer. NMK reports no relevant COI.
Figures
References
-
- Lambertini M, Fontana V, Massarotti C, et al. Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: results of the pilot phase of the PREgnancy and FERtility (PREFER) study. Breast 2018; 41: 51–56. - PubMed
-
- Ruggeri M, Pagan E, Bagnardi V, et al. Fertility concerns, preservation strategies and quality of life in young women with breast cancer: baseline results from an ongoing prospective cohort study in selected European Centers. Breast 2019; 47: 85–92. - PubMed
-
- Lambertini M, Goldrat O, Clatot F, et al. Controversies about fertility and pregnancy issues in young breast cancer patients: current state of the art. Curr Opin Oncol 2017; 29(4): 243–252. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
